asa guidelines for glp-1 drugs Glucagon-Like Peptide-1 Receptor Agonists in Perioperative Care 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations

95% CI 0.19, 2.7) and cyproterone acetate/ethinyl estradiol (WMD: 2.28

Thapa A, Carroll N

GLP-1 GLP-1 , , [35]

Non-acylated GLP-1RAs, such as exenatide, significantly penetrate the BBB and affect brain regions like the hypothalamus, which controls appetite

The most well-established microvascular diseases and disorders include diabetic microvascular complications, small cerebral vessel disease, renal microvascular disease, pulmonary microvascular disease, systemic autoimmune microvascular disorders, and hereditary microangiopathies [155,156,157,158]

As only sub-optimal doses of KBP-089 and liraglutide have been examined chronically, we here evaluate combination-effects of doses that elicits full response separately [13, 14]